Business Wire

TX-ROKA

26.4.2018 20:17:07 CEST | Business Wire | Press release

Share
Javier Gómez Noya Chooses ROKA Eyewear

ROKA , the Austin-based performance design company, has announced a multiyear eyewear partnership with eight-time triathlon world champion and Olympic silver medalist Javier Gómez Noya , expanding their existing relationship for technical race apparel and equipment. Starting in 2018, Gómez will train and race in ROKA’s eyewear, the lightest, most advanced performance optics in the world, in the pursuit of his first Ironman World Championship.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006510/en/

“I first tried the Advanced Performance eyewear while I was at ROKA’s headquarters in Texas, and right away I knew they were the glasses I should be using everyday,” Gómez Noya says. “There’s nothing like them in terms of weight, retention, and quality of vision. Whether cycling or running, you can’t feel that you’re wearing them but you have an incredible field of view.”

Gómez Noya began his partnership with ROKA four years ago, when he chose to compete in ROKA’s innovative line of wetsuits, swimskins, goggles, and triathlon race apparel. Over the past four years, Gómez Noya has worn ROKA to victory in three ITU World Triathlon Series titles, two IRONMAN 70.3 World Championships, and an Xterra Off-Road World Championship. Now he’ll be wearing ROKA optics as well as ROKA’s technical race and swim apparel as he attempts to win his first Ironman World Championship in Hawaii this year and cement his legacy as one of the greatest triathletes of all time.

"Javier has been with us every step of the way over the last four years, so we're thrilled to continue that partnership as we take on the challenge of creating the most advanced optics the world has ever seen," says ROKA CEO and Co-Founder, Rob Canales. "Having the input of an athlete of Javier's caliber is critical to the innovation and development of our products. That now includes our latest Maverick X wetsuit , our technical race apparel, and our advanced optics. We look forward to expanding our work with him to redefine standards in the performance eyewear market. It's about pushing limits, and nobody does that better than Javier.”

Gómez Noya will train and race in ROKA’s recently released Advanced Performance sunglasses, designed from scratch to be the lightest, highest performing, and most comfortable eyewear in the world, with unmatched field of vision and fit. “ROKA’s technical apparel and goggles have been a secret weapon for most of my world championships, and now I’m thrilled to have that same world-beating standard for my eyewear as I take on this new challenge of becoming Ironman World Champion,” Gómez Noya says. “My relationship with ROKA is about working together to make something better, and I’m confident that I now have the best eyewear team in the world in my corner for this next phase of my career.”

ROKA’s Advanced Performance eyewear is available in five styles and up to ten different lens tint options, giving athletes the ability to completely customize their eyewear to fit their specific needs. The unique design is the culmination of years of R&D by ROKA’s world-class team of designers and engineers. Weighing between 21 – 25 grams, the collection has set a new standard in the performance optics market that has to be felt to be believed.

Visit www.roka.com or email sales@roka.com to learn more about the company’s growing lines of premium performance eyewear, apparel, and equipment. Follow ROKA on social media at Facebook , Twitter , and Instagram .

About ROKA

ROKA started in a garage in Austin, Texas with humble beginnings and laser-beam focus. Our mission is to unlock human potential. To equip, empower, inspire, and ignite. We serve those who seek to redefine the standard, to push themselves to the limit – whatever and wherever that may be. When we see an opportunity to innovate, to challenge the status quo, to disrupt a complacent or monopolistic market, we go all in.

Since launching in 2016, ROKA eyewear has been worn to victory by multiple world champions across a variety of sports and challenges, from the Dakar Rally in South America to the Winter Olympics in PyeongChang, South Korea. Gómez Noya is one of 40 elite athletes from all walks of sport who will use Advanced Performance eyewear in 2018, helping them test their limits under the most extreme conditions. For more information, visit www.roka.com/contact

Contact:

Editorial contact
ROKA
Diane Thibert
VP Communications & Public Relations
(310) 804-2400 / diane@roka.com

Link:

ClickThru

Social Media:

https://www.facebook.com/ROKASPORTS/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 14:00:00 CEST | Press release

The partnership, which was announced on stage at LEAP, Combines HUMAIN’s AI Infrastructure Foundation with Together’s AI Native Cloud Platform and Global Reach Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and t

SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release

Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye